

The Evolving Role of Immunotherapy and Radiotherapy in the Non-operative Management of Esophageal and Rectal Cancer

Guest Editors:

Dr. Christopher L. Hallemeier

Department of Radiation
Oncology, Mayo Clinic,
Rochester, MN 55905, USA

Dr. Krishan R. Jethwa

Department of Radiation
Oncology, Mayo Clinic,
Rochester, MN 55905, USA

Dr. Cameron M. Callaghan

Department of Radiation
Oncology, Mayo Clinic,
Rochester, MN 55905, USA

Deadline for manuscript
submissions:

closed (15 October 2023)


Message from the Guest Editors

Dear Colleagues,

This Special Issue welcomes original research that may be preclinical, translational, or clinical regarding radiotherapy or immunotherapy (or preferably both) in the non-operative management of rectal and esophageal cancers. Submissions may also focus on methods of disease surveillance post-therapy, molecular/clinical predictors of response, normal tissue toxicity, and novel treatment strategies to overcome therapeutic resistance. Topics including novel therapeutic agents or interventions for decreasing normal tissue toxicity of either immunotherapy or radiotherapy for esophageal or rectal cancer, as well as predictors of normal tissue toxicity, will also be acceptable. Studies examining the dose, fractionation, and timing of radiotherapy combined with immunotherapy and their differing effects on tumor cell immune evasion, the tumor microenvironment, or pro-inflammatory signaling cascades will also be welcomed. Submissions concerning novel techniques that correlate radiomics and/or pathology with clinical outcomes of radioimmunotherapy in rectal or esophageal cancer are encouraged as well.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)